U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365462) titled 'Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia' on Jan. 22.

Brief Summary: The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Tardive Dyskinesia

Intervention: DRUG: NBI-1065890

Oral administration

DRUG: Placebo

Oral administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Neurocrine Biosciences

Disclaimer: Curated by HT Syndication....